



## Post-grant Opposition System is being Re-introduced for Japanese Patents Effective April 2015

The Japanese Patent Office will re-introduce a post-grant opposition system in April 2015. Under the new opposition system, any party will be able to file an opposition within 6 months of patent issuance. The opposition period starts from the publication date of the granted patent publication (JP B1/B2 publication).

On STN<sup>®</sup>, Japanese B documents are covered in CAplus<sup>SM</sup>, Derwent World Patents Index<sup>®</sup> (DWPI<sup>SM</sup>), INPADOC and JPFULL. For specific search strategies click [here](#).



## Global Value Pricing (GVP) Delivers Real Value to Customers Large and Small

"GVP lets us fully utilize STN without fear about costs."

That's the kind of feedback coming from customers who have taken advantage of STN Global Value Pricing. With unlimited access to STN content, features and interfaces, including new STN, these users enjoy being able to focus on search strategy instead of search costs.

It's no surprise that STN value realization increases - by more than 50% on average - when customers can take full advantage of the content, power and reliability STN offers. All-inclusive, multi-year GVP agreements also save time and effort by improving budget predictability and simplifying administration.

Want to learn more about GVP? Contact your STN representative to find out how [Global Value Pricing](#) can help you maximize the value of STN.



## Is It Necessary to Search CAS REGISTRY<sup>SM</sup>, CAplus and MARPAT<sup>®</sup>?

In most cases, the answer is yes, though it does depend on the goal of your search. CAS REGISTRY, CAplus and MARPAT contain related, complementary information and are designed so they can be searched independently or together. Read more about how CAS REGISTRY, CAplus and MARPAT work for your searches [here](#).



Promising drug candidates sometimes fail during clinical trials because of problems with their delivery. For instance, some compounds are not absorbed well by the body. Other candidates have poor target specificity: they spread through the body rather than going straight to the region where they are needed. This can cause toxicity in healthy tissue. About 20 years ago, pharmaceutical firms began investigating nanomedicines as a potential solution. Because researchers can coat nanoparticles with targeting molecules and can design them to release therapeutic payloads over time, nanomedicines might one day overcome current drug delivery challenges. Click [here](#) for more information on some of the recent patents in this area.

## Database News

### Expanded Regulated Substances Coverage in CHEMLIST® Provides Additional Value to Regulatory Information Professionals

Effective March 2015, CAS coverage of regulated chemicals in CHEMLIST / HCHEMLIST on STN has been enhanced with regulatory information from two additional sources:

- More than 31,000 substances from the Scheduled Chemical Database provided by the Organisation for the Prohibition of Chemical Weapons (OPCW)
- More than 5,800 substances in the Mexican National Inventory of Chemical Substances (Inventario Nacional de Sustancias Químicas, INSQ)

CAS Registry Number® identifiers (CAS RNs) are available for all of the substances in both sources. Please click [here](#) for details.

### Enhanced Coverage of Latin America (Argentina, Mexico) in Derwent World Patents Index®

The country coverage in Derwent World Patents Index (DWPI) has been further enhanced with the renewed inclusion of Argentinian records, relating to both patents and utility models.

This latest addition further extends the global coverage of editorially enhanced content in the file, with data from 51 sources (49 patent-issuing authorities and two journal sources).

## STN® by the numbers

CHEMLIST® on STN now contains information on more than

**243,000**

substances with CAS Registry Number® identifiers whose manufacture, import, export, or transport is subject to regulation by one or more countries.

## Upcoming Training

May 7, 2015  
9:00 am-3:00 pm EDT  
STN Patent Forum  
[Register](#)

View training events [here](#)

## Tradeshows

April 30-May 2, 2015  
Los Angeles, CA  
[AIPLA Spring Meeting](#)

May 2-7, 2015  
Chicago, IL  
[PIUG 2015 Annual Conference](#)

The expanded coverage in DWPI will include all applications for patents and utility models published from January 2015 onwards, including:

- Patent applications (AR A1)
- Divisional patent applications (AR A2)
- Patents of addition (AR A3)
- Utility model applications (AR A4)
- Divisional utility model applications (AR A5)
- Utility model additional applications (AR A6)

The existing coverage of Mexican patents also has been extended with the inclusion of records relating to Mexican utility models. Mexican patent applications and granted patents are already covered in DWPI.

The expanded coverage in DWPI includes all utility models published from September 2014 onwards. Records identified as basics have DWPI titles and abstracts and manual coding, with deep indexing for chemical records where applicable.

The new Mexican utility models have kind code B with a four digit publication number, e.g., MX3138U.

Further details on number formats can be found in the DWPI Reference Center on the [Thomson Reuters website](#).

---

### **INPADOC Now Contains Legal Status Information for Mexico**

Mexican legal status data has been added to INPADOCDB / INPAFAMDB on STN.

INPADOC legal status has been enhanced with legal information from Mexico (MX) beginning with the 2015/12 update. Coverage is provided for important actions during the patent lifetime, such as:

- Invalidations
- Grants of patents or registrations of utility models
- Changes of ownership
- Licenses
- Corrections

A backfile covering legal events, which took place between 2004 and 2014 has been added to the file. Monthly updates are planned. Complete legal status information back to 2004 is provided for covered documents.

June 14-16  
Boston, MA  
[SLA 2015](#)

June 15-18  
Philadelphia, PA  
[BIO International](#)